These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857 [TBL] [Abstract][Full Text] [Related]
3. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. Adami S; Isaia G; Luisetto G; Minisola S; Sinigaglia L; Gentilella R; Agnusdei D; Iori N; Nuti R; J Bone Miner Res; 2006 Oct; 21(10):1565-70. PubMed ID: 16995811 [TBL] [Abstract][Full Text] [Related]
5. Vitamin D status and response to treatment in post-menopausal osteoporosis. Adami S; Giannini S; Bianchi G; Sinigaglia L; Di Munno O; Fiore CE; Minisola S; Rossini M Osteoporos Int; 2009 Feb; 20(2):239-44. PubMed ID: 18551242 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Silverman SL; Watts NB; Delmas PD; Lange JL; Lindsay R Osteoporos Int; 2007 Jan; 18(1):25-34. PubMed ID: 17106785 [TBL] [Abstract][Full Text] [Related]
8. Summaries for patients. Drug therapy for osteoporosis. Ann Intern Med; 2008 May; 148(9):I28. PubMed ID: 18458273 [No Abstract] [Full Text] [Related]
9. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study. Katayama K; Matsuno T Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400 [TBL] [Abstract][Full Text] [Related]
10. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171 [TBL] [Abstract][Full Text] [Related]
11. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338 [TBL] [Abstract][Full Text] [Related]
12. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. Iwamoto J; Takeda T; Sato Y Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196 [TBL] [Abstract][Full Text] [Related]
13. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181 [TBL] [Abstract][Full Text] [Related]
14. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Ettinger MP Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222 [TBL] [Abstract][Full Text] [Related]
15. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice. Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature. Iwamoto J; Sato Y; Takeda T; Matsumoto H Drugs Aging; 2012 Mar; 29(3):191-203. PubMed ID: 22372723 [TBL] [Abstract][Full Text] [Related]
18. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies. Boonen S; Klemes AB; Zhou X; Lindsay R J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865 [TBL] [Abstract][Full Text] [Related]
19. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Tosteson AN; Burge RT; Marshall DA; Lindsay R Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176 [TBL] [Abstract][Full Text] [Related]
20. [Treatment of osteoporosis in the elderly: what is the evidence?]. Verhaar HJ Tijdschr Gerontol Geriatr; 2008 Oct; 39(5):168-75. PubMed ID: 18975841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]